Immucell (ICCC) revenue and earnings history
Immucell reported revenue of $27.6M for fiscal 2025 (year ended Dec 31, 2025), +4.3% on the year before, and net income of −$1.04M.
Over 8 years, from fiscal 2017 to fiscal 2025, revenue grew at a compound rate of +13.0% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $27.6M+4.3% | $1.65M | −$1.04M | $2.48M | $1.25M | $1.22M | $296K | — | — | $3.81M | $9.1M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Immucell (ICCC) on OQRO.
Common questions
What was Immucell's revenue in fiscal 2025?
$27.6M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 30, 2026. That is +4.3% on fiscal 2024 ($26.5M).
How fast has Immucell's revenue grown?
From $10.4M in fiscal 2017 to $27.6M in fiscal 2025: a compound annual growth rate of +13.0% over 8 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Immucell been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Immucell tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
